JP2014505012A - 抗葉酸受容体アルファ抗体の糖型 - Google Patents

抗葉酸受容体アルファ抗体の糖型 Download PDF

Info

Publication number
JP2014505012A
JP2014505012A JP2013535058A JP2013535058A JP2014505012A JP 2014505012 A JP2014505012 A JP 2014505012A JP 2013535058 A JP2013535058 A JP 2013535058A JP 2013535058 A JP2013535058 A JP 2013535058A JP 2014505012 A JP2014505012 A JP 2014505012A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
fra
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013535058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505012A5 (enExample
Inventor
フィリップ エム． サス，
ニコラス ニコライデス，
ルイージ グラッソ，
エリック ローシアー，
ウェイ グー，
ジェイソン ヤン，
ジュン ヤオ，
Original Assignee
モーフォテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モーフォテック， インコーポレイテッド filed Critical モーフォテック， インコーポレイテッド
Publication of JP2014505012A publication Critical patent/JP2014505012A/ja
Publication of JP2014505012A5 publication Critical patent/JP2014505012A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013535058A 2010-10-20 2011-10-19 抗葉酸受容体アルファ抗体の糖型 Pending JP2014505012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Publications (2)

Publication Number Publication Date
JP2014505012A true JP2014505012A (ja) 2014-02-27
JP2014505012A5 JP2014505012A5 (enExample) 2014-12-04

Family

ID=45975873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535058A Pending JP2014505012A (ja) 2010-10-20 2011-10-19 抗葉酸受容体アルファ抗体の糖型

Country Status (12)

Country Link
US (1) US20120164137A1 (enExample)
EP (1) EP2629798A4 (enExample)
JP (1) JP2014505012A (enExample)
KR (1) KR20140032944A (enExample)
CN (1) CN103347537A (enExample)
AU (2) AU2011317088B2 (enExample)
BR (1) BR112013009275A2 (enExample)
CA (1) CA2815080A1 (enExample)
IL (1) IL225579A0 (enExample)
MX (1) MX2013004202A (enExample)
RU (1) RU2013122843A (enExample)
WO (1) WO2012054654A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170083636A (ko) * 2014-12-01 2017-07-18 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239910A1 (en) * 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
ES2766836T3 (es) * 2012-05-15 2020-06-15 Eisai Inc Métodos para el tratamiento de cáncer gástrico
HRP20200482T1 (hr) * 2012-08-31 2020-06-26 Immunogen, Inc. Dijagnostičke analize i setovi za detekciju folat receptora 1
CA2893378A1 (en) * 2012-12-07 2014-06-12 Kyowa Hakko Kirin Co., Ltd. Anti-folr1 antibody
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
CA2921975C (en) 2013-08-30 2024-02-13 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
MA40972B1 (fr) 2014-11-20 2020-11-30 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
JP6944369B2 (ja) 2014-11-20 2021-10-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法
PT3221357T (pt) 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
IL257531B2 (en) 2015-09-17 2023-04-01 Immunogen Inc Medicinal compositions containing anti-folr1 immunoconjugates
EA202092125A1 (ru) 2018-03-13 2020-12-15 Фейнз Терапьютикс, Инк. Антитела против рецептора фолата 1 и их применения
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500025A (ja) * 2004-02-12 2008-01-10 モルフォテック、インク． 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
JP2009521206A (ja) * 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648511A1 (en) * 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2005274905B2 (en) * 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
CN103242451B (zh) * 2005-12-16 2017-11-21 Ibc医药公司 基于免疫球蛋白的多价生物活性装配体
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500025A (ja) * 2004-02-12 2008-01-10 モルフォテック、インク． 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
JP2009521206A (ja) * 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOL. PROG., vol. 21, JPN6015035309, 2005, pages 1 - 16, ISSN: 0003148332 *
CLIN. CANCER RES., vol. 16, no. 21, JPN6015035305, September 2010 (2010-09-01), pages 5288 - 5295, ISSN: 0003148329 *
GLYCOBIOLOGY, vol. 19, no. 9, JPN6015035306, 2009, pages 936 - 949, ISSN: 0003148330 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 5, JPN6015035310, 2003, pages 3466 - 3473, ISSN: 0003148333 *
PHARMACEUTICALS, vol. 3, JPN6015035308, January 2010 (2010-01-01), pages 146 - 157, ISSN: 0003148331 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170083636A (ko) * 2014-12-01 2017-07-18 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법
JP2017538446A (ja) * 2014-12-01 2017-12-28 アムジエン・インコーポレーテツド 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
JP2020124216A (ja) * 2014-12-01 2020-08-20 アムジエン・インコーポレーテツド 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
US10822630B2 (en) 2014-12-01 2020-11-03 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
JP7066775B2 (ja) 2014-12-01 2022-05-13 アムジエン・インコーポレーテツド 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
KR102623965B1 (ko) 2014-12-01 2024-01-11 암젠 인크 당단백질의 글리칸 함량 수준을 조작하는 방법

Also Published As

Publication number Publication date
MX2013004202A (es) 2013-10-17
EP2629798A4 (en) 2014-05-28
CN103347537A (zh) 2013-10-09
AU2011317088A1 (en) 2013-05-02
AU2011317088B2 (en) 2016-01-21
RU2013122843A (ru) 2014-11-27
WO2012054654A2 (en) 2012-04-26
CA2815080A1 (en) 2012-04-26
BR112013009275A2 (pt) 2017-06-20
IL225579A0 (en) 2013-06-27
EP2629798A2 (en) 2013-08-28
US20120164137A1 (en) 2012-06-28
WO2012054654A3 (en) 2012-08-02
AU2016202082A1 (en) 2016-04-28
KR20140032944A (ko) 2014-03-17

Similar Documents

Publication Publication Date Title
AU2011317088B2 (en) Anti-folate receptor alpha antibody glycoforms
ES2691794T3 (es) Anticuerpo anti-FOLR1
RU2710717C2 (ru) Молекулы, связывающиеся с 4-1ВВ
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
JP2021510535A (ja) Ｈｅｒ３抗原結合性分子
RS59642B1 (sr) Supstance antitela za lečenje tumora
WO2011155579A1 (ja) 抗Ｔｒｏｐ－２抗体
KR20190068521A (ko) 혈액암을 치료하기 위한 항-cd20 항체, pi3 키나아제-델타 억제제, 및 항-pd-1 또는 항-pd-l1 항체의 조합
JP2021508467A (ja) 抗ｌａｇ−３抗体及びその使用
US20240002503A1 (en) Novel anti-lilrb2 antibodies and derivative products
EP4467571A1 (en) Anti-cd3 and anti-cd20 bispecific antibody and use thereof
TW202035448A (zh) 有效表現之egfr及pd-l1雙特異性結合蛋白
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
CN112424357A (zh) 与硫酸软骨素蛋白聚糖5结合的抗体
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
EP3211080B1 (en) Anti human gas6 monoclonal antibodies
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
WO2023072294A1 (en) Novel anti-lag3 antibodies
TW202542201A (zh) 抗psma軛合物及其使用方法
TW202523694A (zh) 抗muc16抗體及其用途
HK40047611A (en) Antibody binding to chondroitin sulfate proteoglycan-5
EA039429B1 (ru) Способы лечения опухолей с применением биспецифического антитела cd3xcd20

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170209